TriSalus Life Sciences reports Q4 EPS (40c), consensus (35c)

Reports Q4 revenue $8.26M, consensus $8.24M. “We achieved commercial and clinical progress throughout 2024, and positioning TriSalus for greater success in 2025,” said Mary Szela, president and CEO of TriSalus Life Sciences (TLSI). “We achieved $29.4 million in total revenue, marking 59% growth year-over-year, and continue to expect to deliver greater than 50% revenue growth in 2025. Additionally, we anticipate reducing operating expenses by more than 20%, achieving positive EBITDA for the full year, and achieving positive cash flow in the second half of the year.”